Search results for " antiviral agents"

showing 5 items of 75 documents

Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

2017

We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of fibrosis stage; policy 2, treat only “prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus–infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were us…

hepatitis C virusPediatricsCost effectivenessViral HepatitisAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; HepatologyCost-Benefit AnalysisDirect-acting antiviralAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models EconomicCohort StudiesLiver disease0302 clinical medicineModelsHealth careantiviral therapy80 and overincremental cost-effectiveness ratiohealth care economics and organizationsHCV cost -effectivenessAged 80 and overDirect-acting antiviral hepatocellular carcinoma hepatitis C virus incremental cost-effectiveness ratio interferon quality-adjusted life-years sustained virological response willingness to payCost–benefit analysis030503 health policy & servicesquality-adjusted life-yearsHealth PolicyHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CModels EconomicAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; Hepatology; HCV; antiviral therapy; cost-effectiveness; real-life cohortCohortHCV030211 gastroenterology & hepatologyOriginal Articlesustained virological response0305 other medical scienceCohort studyHumanAdultmedicine.medical_specialtyEconomicAntiviral AgentsNO03 medical and health sciencesYoung Adultreal-life cohortmedicineHumansCost-Benefit Analysicost-effectivenessHealth policyAgedAntiviral AgentHepatologybusiness.industryOriginal Articlesmedicine.diseaseSurgeryCohort Studiebusinesswillingness to pay
researchProduct

Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C

2021

INTRODUCTION: In the last years the Hepatitis C virus (HCV) infection was a relevant public health problem due to the large number of affected people worldwide and the impact on hepatic and extrahepatic complications. The availability of direct-acting antivirals (DAAs) and the very high rate of sustained virological response (SVR) after treatment has radically changed the course of HCV chronic infection. EVIDENCE ACQUISITION: We searched PubMed for articles published between January 1, 1995, through December 31, 2020, in English language. EVIDENCE SYNTHESIS: Robust evidence showed a close link between HCV infection and development of cardiovascular disease (CVD), as result of the atherogeni…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHepatitis C virusMEDLINEHepacivirusDiseaseDIRECT ACTING ANTIVIRALSmedicine.disease_causeAntiviral AgentsVirusInternal medicineInternal MedicinemedicineHumansHepatitis chronic Cardiovascular diseases Antiviral agentsIn patientbusiness.industryPublic healthGastroenterologyvirus diseasesHepatitis C Chronicdigestive system diseasesChronic infectionCardiovascular DiseasesPersistent Infectionbusiness
researchProduct

Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19

2021

Key Points Three-day change in angiopoietin-2 levels predicts COVID-19 in-hospital mortality, whereas the 10-day trend is associated with chronic lung disability. Angiopoietin-2 may play an important pathogenic role in patients with COVID-19, and it could be a target for new treatments.

medicine.medical_specialtyMultivariate analysis20CD34Risk Factors ...030204 cardiovascular system & hematologyGastroenterologyAntiviral AgentsAngiopoietin-203 medical and health sciences0302 clinical medicineRisk FactorsVascular BiologyInternal medicinemedicineHumans030212 general & internal medicineHospital MortalitySurvival rateProportional Hazards ModelsAntiviral AgentLungReceiver operating characteristicbusiness.industryProportional hazards modelSARS-CoV-2Interleukin-6Risk FactorHazard ratioCOVID-19HematologyBiomarker32Confidence intervalCOVID-19 Drug TreatmentHospitalizationSurvival RateAngiopoietin-2; Antiviral Agents; Area Under Curve; Biomarkers; COVID-19; Hospital Mortality; Hospitalization; Humans; Interleukin-6; Proportional Hazards Models; ROC Curve; Risk Factors; SARS-CoV-2; Survival Ratemedicine.anatomical_structureROC CurveArea Under Curvecardiovascular systemProportional Hazards ModelbusinessBiomarkersHuman
researchProduct

AISF position paper on HCV in immunocompromised patients.

2018

Abstract This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

medicine.medical_specialtyTransplant RecipientComorbidityAntiviral AgentsOrgan transplantation03 medical and health sciencesImmunocompromised Host0302 clinical medicineInternal medicineNeoplasmsmedicineImmunocompromised patientHumansChronicIntensive care medicineAntiviral AgentHepatologybusiness.industryGastroenterologyHepatologyHepatitis C Chronicmedicine.diseaseComorbidityHepatitis COrgan transplantHCV; Immunocompromised patients; Organ transplant; Hepatology; GastroenterologyTransplant RecipientsHCV; Immunocompromised patients; Organ transplant; Antiviral Agents; Comorbidity; Hepatitis C Chronic; Humans; Immunocompetence; Italy; Neoplasms; Transplant Recipients; Immunocompromised HostItaly030220 oncology & carcinogenesisHCVHCV Immunocompromised patients Organ transplantPosition paperNeoplasmImmunocompromised patients030211 gastroenterology & hepatologyImmunocompetencebusinessImmunocompetenceDirect actingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and prot…

2006

ABSTRACTRotavirus (RV) is the main etiological agent of severe gastroenteritis in infants, and vaccination seems the most effective way to control the disease. Recombinant rotavirus-like particles composed of the viral protein 6 (VP6) and VP2 (2/6-VLPs) have been reported to induce protective immunity in mice when administered by the intranasal (i.n.) route. In this study, we show that administration of 2/6-VLPs by the intrarectal (i.r.) route together with either cholera toxin (CT) or a CpG-containing oligodeoxynucleotide as the adjuvant protects adult mice against RV infection. Moreover, when CT is used, RV shedding in animals immunized by the i.r. route is even reduced in comparison with…

medicine.medical_treatmentMESH : Cytokinesanimal diseasesMESH : Oligodeoxyribonucleotidesmedicine.disease_causeAntibodies ViralImmunoglobulin GMiceIntestinal mucosaMESH: RectumRotavirusMESH : FemaleMESH: AnimalsViralIntestinal MucosaInbred BALB C0303 health sciencesMice Inbred BALB CMESH: CytokinesMESH : Cholera ToxinMESH : Immunoglobulin A SecretoryMESH: Rotavirus Infections3. Good healthMESH : Rotavirus VaccinesVaccinationmedicine.anatomical_structureOligodeoxyribonucleotides[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH : RectumMESH: Intestinal MucosaCytokinesMESH: VirionMESH: ImmunizationFemaleAdjuvantMESH : Antibodies ViralCholera ToxinImmunologyMESH: Mice Inbred BALB CSpleenchemical and pharmacologic phenomenaBiologyMicrobiologyMESH : Intestinal Mucosa[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH: Rotavirus VaccinesRotavirus InfectionsAntibodies03 medical and health sciencesImmune systemVirologyVaccines and Antiviral AgentsMESH : MicemedicineMESH : Rotavirus InfectionsMESH : VirionAnimalsMESH: MiceMESH : Mice Inbred BALB CMESH: Cholera Toxin030304 developmental biology030306 microbiologyRotavirus VaccinesRectumVirionMESH : Immunizationbiochemical phenomena metabolism and nutritionSecretoryVirologyImmunoglobulin AMESH: Immunoglobulin A SecretoryImmunizationInsect ScienceImmunologyImmunoglobulin A Secretorybiology.proteinMESH: OligodeoxyribonucleotidesbacteriaImmunizationMESH : AnimalsMESH: FemaleMESH: Antibodies Viral
researchProduct